<code id='DD004334B1'></code><style id='DD004334B1'></style>
      • <acronym id='DD004334B1'></acronym>
      <center id='DD004334B1'><center id='DD004334B1'><tfoot id='DD004334B1'></tfoot></center><abbr id='DD004334B1'><dir id='DD004334B1'><tfoot id='DD004334B1'></tfoot><noframes id='DD004334B1'>
      • <optgroup id='DD004334B1'><strike id='DD004334B1'><sup id='DD004334B1'></sup></strike><code id='DD004334B1'></code></optgroup>
        5. <b id='DD004334B1'><label id='DD004334B1'><select id='DD004334B1'><dt id='DD004334B1'><span id='DD004334B1'></span></dt></select></label></b><u id='DD004334B1'></u>
          <i id='DD004334B1'><strike id='DD004334B1'><tt id='DD004334B1'><pre id='DD004334B1'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / explore / knowledge      
           
     
           
      
          knowledge 
           
      
           
      
           
       2025-10-01 18:48:36 
   
      
           
      
           
                        
          knowledge  
          
                                   
                 
                                      author：explore   
                                        
                                      
                                      Page View：2
                                  
                                    
          
                                   
          Editor’s note: A recording of the event is embedded below.
          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
          advertisement
          Featured Speakers
          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more
                                
                            
          Next article：  
                                      
                                          Apple is now the first public company to be valued at $3 trillion
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles